Endocrine Abstracts

Background: Treatment outcome with hydrocortisone for congenital adrenal hyperplasia (CAH) in neonates and children is highly variable. As there is no licensed formulation for children <6 years hydrocortisone capsules individually have to be compounded by local pharmacies (dose strength: 0.5–9.5 mg). The aim of this study was to characterise mass and content of these capsules in order to assess medication safety for effective and nontoxic dosing in terms of precision ...

Cushing disease is a rare endocrine disorder characterised by excess production of adrenocorticotropic hormone (ACTH) from a pituitary adenoma causing an excessive stimulation of the adrenal glands resulting in hypercortisolism. Most common clinical presentation includes a combination of signs like central obesity, facial plethora,ecchymosis, purple skin striae, hirsutism, acne, muscle weakness and atrophy. Hypertension, glucose intolerance and diabetes, hypokalaemia and osteo...

Background: Current standard treatment for adrenal insufficiency in neonates and infants is unsatisfactory as unlicensed adult dosage formulations are used. These are generally difficult to administer and may give rise to inconsistencies in dose as the content uniformity of the dosage form cannot be verified.Methods: Infacort is a newly-developed immediate release formulation of hydrocortisone that is provided in appropriate unit dosage units (0.5, 1, 2,...